EWA
RNTX

Exencial Wealth Advisors’s Rein Therapeutics RNTX Stock Holding History

Exencial Wealth Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.7K Buy
+30,528
New +$37.9K ﹤0.01% 561
2025
Q4 		– Sell
-30,528
Closed -$35K – 573
2025
Q3 		$35K Hold
30,528
– – ﹤0.01% 518
2025
Q2 		$42.7K Hold
30,528
– – ﹤0.01% 486
2025
Q1 		$54K Hold
30,528
– – ﹤0.01% 493
2024
Q4 		$70.2K Buy
+30,528
New +$92.5K ﹤0.01% 497

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Exencial Wealth Advisors's RNTX Position: Q1 2026 in Review

Exencial Wealth Advisors opened a new position in Rein Therapeutics (RNTX) in Q1 2026: 30,528 shares worth $39.7K. The stake represents ﹤0.01% of the portfolio and ranks #561 among its holdings. This is a return to the name: Exencial Wealth Advisors previously reported a position in RNTX as recently as Q3 2025.

Exencial Wealth Advisors first reported a position in RNTX in Q4 2024 and has held it in 5 quarters since. The position peaked at $70.2K in Q4 2024. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Exencial Wealth Advisors held 30,528 shares of Rein Therapeutics worth $39.7K as of Q1 2026.
  • Rein Therapeutics was a new Exencial Wealth Advisors position in Q1 2026.
  • Rein Therapeutics made up ﹤0.01% of Exencial Wealth Advisors's portfolio in Q1 2026, its #561 holding.
  • Exencial Wealth Advisors first reported a position in Rein Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Exencial Wealth Advisors's Rein Therapeutics position peaked at $70.2K in Q4 2024.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Exencial Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.